Clinical Findings and Outcome of ALK+Lymphoma
Characteristic . | ALK+ . | ||
---|---|---|---|
Alive (N = 40) . | Died (N = 13) . | P . | |
Sex | |||
M | 30 | 10 | NS |
F | 10 | 3 | |
Age (yr) | |||
≤35 | 36 | 11 | NS |
>35 | 4 | 2 | |
Performance status | |||
0-1 | 22 | 3 | .008 |
>1 | 11 | 10 | |
B symptoms | |||
No | 11 | 2 | NS |
Yes | 29 | 11 | |
Bulky disease | |||
No | 30 | 10 | NS |
Yes | 10 | 3 | |
Extranodal sites | |||
No | 21 | 0 | .001 |
Yes | 19 | 13 | |
Extranodal sites | |||
Skin | 6 | 5 | |
Bone | 6 | 3 | |
Bone marrow | 3 | 3 | |
Lung | 3 | 3 | |
Ann Arbor stage | |||
I-II | 14 | 1 | NS |
III-IV | 26 | 12 | |
LDH level | |||
<1× normal | 21 | 6 | NS |
>1× normal | 15 | 5 | |
International Prognostic Index | |||
0-1 (low/low intermediate) | 24 | 1 | .001 |
≥2 (high/high intermediate) | 13 | 12 |
Characteristic . | ALK+ . | ||
---|---|---|---|
Alive (N = 40) . | Died (N = 13) . | P . | |
Sex | |||
M | 30 | 10 | NS |
F | 10 | 3 | |
Age (yr) | |||
≤35 | 36 | 11 | NS |
>35 | 4 | 2 | |
Performance status | |||
0-1 | 22 | 3 | .008 |
>1 | 11 | 10 | |
B symptoms | |||
No | 11 | 2 | NS |
Yes | 29 | 11 | |
Bulky disease | |||
No | 30 | 10 | NS |
Yes | 10 | 3 | |
Extranodal sites | |||
No | 21 | 0 | .001 |
Yes | 19 | 13 | |
Extranodal sites | |||
Skin | 6 | 5 | |
Bone | 6 | 3 | |
Bone marrow | 3 | 3 | |
Lung | 3 | 3 | |
Ann Arbor stage | |||
I-II | 14 | 1 | NS |
III-IV | 26 | 12 | |
LDH level | |||
<1× normal | 21 | 6 | NS |
>1× normal | 15 | 5 | |
International Prognostic Index | |||
0-1 (low/low intermediate) | 24 | 1 | .001 |
≥2 (high/high intermediate) | 13 | 12 |
Abbreviation: NS, not significant.